IL-6 (Interleukin-6) is a pleiotropic cytokine that plays complex roles in the nervous system, functioning as both a pro-inflammatory mediator and a neurotrophic factor. It is critically involved in the neuroinflammation that characterizes Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. This page provides comprehensive information about IL-6 structure, signaling mechanisms, normal neural functions, and its pathological roles in neurodegenerative diseases.
--- [1]
title: IL-6 Protein [2]
description: IL-6 Interleukin-6 - Pleiotropic cytokine in neuroinflammation and neurodegeneration [3]
--- [4]
| | | [5]
|---|---| [6]
| Protein Name | Interleukin-6 (IL-6) | [7]
| Gene | IL6 | [8]
| UniProt ID | P05231 |
| PDB ID | 1ALU, 1IL6, 2LA3 |
| Molecular Weight | 26 kDa (native), 20.7 kDa (monomer) |
| Amino Acids | 212 |
| Structure | Four-helix bundle cytokine fold |
| Receptors | IL6R (membrane), gp130 (signal transducing) |
IL-6 is a member of the gp130 cytokine family that exhibits remarkable functional pleiotropy. It acts on virtually every cell type in the body, including neurons, astrocytes, microglia, and oligodendrocytes in the CNS. In the brain, IL-6 is involved in normal processes including synaptic plasticity, neurogenesis, and neural development, but chronic dysregulation contributes to neurodegenerative pathology.
The complexity of IL-6 signaling arises from multiple receptor configurations:
IL-6 is synthesized as a 212-amino acid polypeptide:
IL-6 adopts the classic four-helix bundle topology:
IL-6 interacts with:
JAK-STAT Pathway:
MAPK Pathway:
PI3K-AKT Pathway:
Soluble IL-6R (sIL-6R) can bind IL-6 and trigger gp130 signaling in cells lacking membrane IL-6R:
IL-6 shares gp130 signaling with:
This explains overlapping biological activities.
CNS IL-6 is normally kept at low levels (pg/mL range in CSF):
IL-6 is heavily implicated in AD pathogenesis:
Expression patterns:
Pathogenic mechanisms:
Genetic associations:
Therapeutic implications:
In PD, IL-6 contributes to dopaminergic neuron degeneration:
Expression patterns:
Pathogenic mechanisms:
Therapeutic implications:
IL-6 plays complex roles in ALS:
Expression patterns:
Pathogenic mechanisms:
Controversy:
IL-6 is central to MS pathophysiology:
Expression patterns:
Pathogenic mechanisms:
Therapeutic success:
| Agent | Target | Route | Indications |
|---|---|---|---|
| Tocilizumab | IL-6R | IV/SC | RA, Giant cell arteritis, CRS |
| Sarilumab | IL-6R | SC | RA |
| Siltuximab | IL-6 | IV | Castleman disease |
| Satralizumab | IL-6R | SC | NMOSD |
Block IL-6 signaling downstream:
IL-6 has biomarker utility:
IL-6 polymorphisms affect disease risk:
IL-6 is a pivotal cytokine in neurodegenerative disease pathogenesis, bridging systemic inflammation and CNS pathology. While essential for normal neural development and function, chronic IL-6 elevation drives neuroinflammation in AD, PD, ALS, and MS. The success of IL-6R blockade in autoimmune conditions has validated this pathway as a therapeutic target, though CNS penetration remains a challenge. Understanding the dual pro-inflammatory and neurotrophic roles of IL-6 is essential for developing targeted therapies.
The study of Il 6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011. ↩︎
Erta M, Hidalgo A, Alcocer J, Lovel H, Quintanar T. Interleukin-6 (IL-6) in the central nervous system: role in physiological functions and pathological states. Int J Biol Sci. 2012. ↩︎
Rothaug M, Zunke F, Mazzu C, Lülldorf F, Kalbacher H. IL-6 in neurodegeneration: friend or foe? J Neuroinflammation. J Neuroinflammation. 2016. ↩︎
Geppert AM, Dzwonek K. IL-6 in synaptic plasticity in healthy and diseased brain. Neural Plast. 2018. ↩︎
Quintanar T, García G, Montes S, et al. IL-6 in Parkinson's disease: neuroinflammation and therapeutic targeting. Mol Neurobiol. 2021. ↩︎
Brunner M, Ktle C, Kutzner C, et al. IL-6 in ALS: biomarker or therapeutic target? J Neurol Sci. J Neurol Sci. 2020. ↩︎
Kalliolias GD, Ivashkiv LB. IL-6 signaling in autoimmunity, inflammation and cancer. J Exp Med. 2016. ↩︎
Stojkovic G, Thiel J, Becher B. IL-6: a dirty word or just a misunderstood cytokine in multiple sclerosis? Trends Neurosci. Trends Neurosci. 2021. ↩︎